NCT02350517View on ClinicalTrials.gov

Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2022

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Paclitaxel+Nedaplatin+Endostar

Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Yuhong Li

OTHER

NCT02350517 - Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer | Biotech Hunter | Biotech Hunter